FAM110A and breast cancer: Patient samples from this study were previously used to identify a four-marker panel including PITX2, BMP4, FGF4, and C20orf55 which enabled outcome prediction in lymph node-positive, HER-2-negative breast cancer patients treated with anthracycline-based chemotherapy [14].